PTPN11 and chronic myelogenous leukemia, BCR-ABL1 positive: Among others, these resistance-promoting pathways can be specifically activated by pathogenic PTPN11 gain-of-function gene mutations, which have been identified in myeloid malignancies, including tyrosine kinase inhibitor (TKI)-resistant CML and AML [10].